>>Description of the research protocol "HEP101"

HEP101 Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with acute-on-chronic liver failure
Phase II study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Foie
Brugmann identifier : HEP101
EudraCT identifier : 2016-001177-32
ClinicalTrials.gov identifier : NCT02946554


Involved department : Gastroenterology
Principal investigator : Lasser
Sponsor : Promethera
Contact : Clinical Research Unit

>This protocol was approved by the KU Leuven ethics committee.